Supplemental Table 1. Overview of treatment emergent adverse events in the safety population

	Imeglimin (n=106)	Placebo (n=107)
Patients with any TEAEs	47 (44.2%)	48 (44.9%)
Patients with mild TEAEs	44 (41.5%)	46 (43.0%)
Patients with moderate TEAEs	5 (4.7%)	4 (3.7%)
Patients with severe TEAEs	2 (1.9%)	1 (0.9%)
Patients with any treatment related TEAEs	5 (4.7%)	7 (6.5%)
Patients with any TEAEs leading to premature study drug discontinuation	3 (2.8%)	6 (5.6%)
Patients with any SAE	4 (3.8%)	1 (0.9%)
Femur fracture	1 (0.9%)	0
Lower limb fracture	0	1 (0.9%)
Radius fracture	1 (0.9%)	0
Ileus	1 (0.9%)	0
Bladder cancer	1 (0.9%)	0
Spondylotic myelopathy	1 (0.9%)	0
Death	0	0

Data are n (%).

Supplemental Table 2. Gastrointestinal and hypoglycemic events in the safety population

	Imeglimin (n=106)	Placebo (n=107)
	N (%) n	N (%) n
Gastrointestinal disorders	**12 (11.3%) 15**	**9 (8.4%) 9**
Constipation	2 (1.9%) 2	1 (0.9%) 1
Dental Caries	1 (0.9%) 1	2 (1.9%) 2
Abdominal pain upper	1 (0.9%) 1	1 (0.9%) 1
Diarrhoea	1 (0.9%) 1	1 (0.9%) 1
Duodenal ulcer	0	2 (1.9%) 2
Faeces soft	0	2 (1.9%) 2
Gastritis	2 (1.9%) 2	0
Abdominal discomfort	1 (0.9%) 1	0
Abdominal distension	1 (0.9%) 1	0
Abdominal pain	1 (0.9%) 1	0
Epigastric discomfort	1 (0.9%) 1	0
Ileus	1 (0.9%) 1	0
Large intestine polyp	1 (0.9%) 1	0
Periodontal disease	1 (0.9%) 1	0
Vomiting	1 (0.9%) 1	0
Hypoglycemia	**3 (2.8%) 7**	**1 (0.9%) 2**
Documented symptomatic hypoglycemia	1 (0.9%) 2	0
Asymptomatic hypoglycemia reported from SMBG	2 (1.9%) 5	1 (0.9%) 2
Severe hypoglycemia	0	0

N: Number of patients; n: number of events

Supplemental Table 3. Baseline and end-of-treatment values of lipid parameters

	Imeglimin (n=106)	Placebo (n=106)
	Mean (SD)	Mean (SD)
Total cholesterol (mmol/L)		
Baseline	5.019 (0.92)	5.198 (0.84)
Week 24	5.161 (0.94)	5.123 (0.84)
LDL-c (mmol/L)		
Baseline	2.887 (0.84)	2.998 (0.76)
Week 24	3.041 (0.84)	2.946 (0.75)
HDL-c (mmol/L)		
Baseline	1.435 (0.46)	1.451 (0.41)
Week 24	1.405 (0.43)	1.456 (0.49)
Triglycerides (mmol/L)		
Baseline	1.525 (0.77)	1.771 (1.54)
Week 24	1.563 (0.78)	1.717 (1.78)